Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 219 KB, PDF-dokument

  • Arthur E. Frankel
  • Renuka Reddy
  • Kayla R. DeSuza
  • Khaled Deeb
  • Aaron F. Carlin
  • Davey Smith
  • Yushuang Xie
  • Eknath Naik
  • Richard T. Silver
  • Hasselbalch, Hans K

An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.

OriginalsprogEngelsk
TidsskriftClinical Case Reports
Vol/bind9
Udgave nummer4
Sider (fra-til)2228-2235
Antal sider8
ISSN2050-0904
DOI
StatusUdgivet - 2021

Bibliografisk note

Publisher Copyright:
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

ID: 305536197